毒性多结节性甲状腺肿

Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. Endocr Pract. 2016;22(Suppl 1):1-60.

• 全文
• 摘要

Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343-1421.

• 全文
• 摘要

1.  Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. Endocr Pract. 2016;22(Suppl 1):1-60.

• 全文
• 摘要

2.  Gabriel EM, Bergert ER, Grant CS, et al. Germline polymorphism of codon 727 of human thyroid-stimulating hormone receptor is associated with toxic multinodular goiter. J Clin Endocrinol Metab. 1999;84:3328-3335.

• 全文
• 摘要

3.  Tonacchera M, Vitti P, De Servi M, et al. Gain of function TSH receptor mutations and iodine deficiency: implications in iodine prophylaxis. J Endocrinol Invest. 2003;26(suppl 2):2-6.

• 摘要

4.  Niedziela M, Breborowicz D, Trejster E, et al. Hot nodules in children and adolescents in western Poland from 1996 to 2000: clinical analysis of 31 patients. J Pediatr Endocrinol Metab. 2002;15:823-830.

• 摘要

5.  Tonacchera M, Chiovato L, Pinchera A, et al. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating thyrotropin receptor mutations with solitary toxic adenoma. J Clin Endocrinol Metab. 1998;83:492-498.

• 全文
• 摘要

6.  Tonacchera M, Agretti P, Chiovato L, et al. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter. J Clin Endocrinol Metab. 2000;85:2270-2274.

• 全文
• 摘要

7.  Krohn K, Führer D, Bayer Y, et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev. 2005;26:504-524.

• 全文
• 摘要

8.  Derwahl M. TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas - a note of caution. J Clin Endocrinol Metab. 1996;81:2783-2785.

• 摘要

9.  Morris AJ, Malbon CC. Physiological regulation of G protein-linked signaling. Physiol Rev. 1999;79:1373-1430.

• 摘要

10.  Poertl S, Kirner J, Saller B, et al. T3-release from autonomously functioning thyroid nodules in vitro. Exp Clin Endocrinol Diabetes. 1998;106:489-493.

• 摘要

11.  Polak M. Hyperfunctioning thyroid adenoma and activating mutations in the TSH receptor gene. Arch Med Res. 1999;30:510-513.

• 摘要

12.  Krohn K, Führer D, Holzapfel HP, et al. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations. J Clin Endocrinol Metab. 1998;83:130-134.

• 摘要

13.  Derwahl M, Hamacher C, Russo D, et al. Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas. J Clin Endocrinol Metab. 1996;81:1898-1904.

• 摘要

14.  Pearce EN, Pino S, He X, et al. Sources of dietary iodine: bread, cows' milk, and infant formula in the Boston area. J Clin Endocrinol Metab. 2004;89:3421-3424.

• 摘要

15.  Reid JR, Wheeler SF. Hyperthyroidism: diagnosis and treatment. Am Fam Physician. 2005;72:623-630.

• 摘要

16.  Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;26:348:2646-2655. [Erratum in: N Engl J Med. 2003;349:620.]

• 摘要

17.  Cooper DS. Hyperthyroidism. Lancet. 2003;362:459-468.

• 摘要

18.  De Filippis EA, Sabet A, Sun MR, et al. Pemberton's sign: explained nearly 70 years later. J Clin Endocrinol Metab. 2014;99:1949-1954.

• 摘要

19.  Belfiore A, La Rosa GL, La Porta GA, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med. 1992;93:363-369.

• 摘要

20.  Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343-1421.

• 全文
• 摘要

21.  Perrild H, Hansen JM, Skovsted L, et al. Different effects of propranolol, alprenolol, sotalol, atenolol and metoprolol on serum T3 and serum rT3 in hyperthyroidism. Clin Endocrinol (Oxf). 1983;18:139-142.

• 摘要

22.  Cooper DS, Daniels GH, Ladenson PW, et al. Hyperthyroxinemia in patients treated with high-dose propranolol. Am J Med.1982;73:867-871.

• 摘要

23.  Nygaard B, Hegedus L, Ulriksen P, et al. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med. 1999;159:1364-1368. 

• 摘要

24.  Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905-917.

• 摘要

25.  Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27:315-389.

• 全文
• 摘要

26.  Porterfield JR Jr, Thompson GB, Farley DR, et al. Evidence-based management of toxic multinodular goiter (Plummer's Disease). World J Surg. 2008;32:1278-1284.

• 摘要

27.  Vadiveloo T, Donnan PT, Cochrane L, et al. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab. 2011;96:1344-1351.

• 摘要

28.  Lee JS, Bužková P, Fink HA, et al. Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med. 2010;170:1876-1883.

• 全文
• 摘要

29.  Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379:1142-1154.

• 摘要

30.  Gharib H, Tuttle RM, Baskin HJ, et al. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab. 2005;90:581-585; discussion 586-587.

• 全文
• 摘要

31.  Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-238.

• 全文
• 摘要

32.  Pearce EN. Diagnosis and management of thyrotoxicosis. BMJ. 2006;332:1369-1373.

• 摘要

33.  Adam MA, Thomas S, Youngwirth L, et al. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Ann Surg. 2017;265:402-407.

• 摘要

34.  Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet. 2012;379:1155-1166.

• 摘要

35.  Toft AD. Clinical practice. Subclinical hyperthyroidism. N Engl J Med. 2001;345:512-516.

• 摘要

36.  Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95:186-193.

• 摘要

37.  Blum MR, Bauer DC, Collet TH, et al. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015;313:2055-2065.

• 摘要

38.  Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. Ann Intern Med. 1999;130:750-758.

• 摘要

39.  Sisson JC, Freitas J, McDougall IR, et al; American Thyroid Association Taskforce On Radioiodine Safety. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011;21:335-346.

• 全文
• 摘要